世界の高リン血症治療薬市場

【英語タイトル】GLOBAL HYPERPHOSPHATEMIA DRUG MARKET FORECAST 2018-2026

Inkwood Researchが出版した調査資料(INKW807061)・商品コード:INKW807061
・発行会社(調査会社):Inkwood Research
・発行日:2018年4月16日
・ページ数:127
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:PHARMACEUTICALS
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥270,000見積依頼/購入/質問フォーム
Multi LicenseUSD3,000 ⇒換算¥324,000見積依頼/購入/質問フォーム
Enterprisewide Price (Global Site License)USD4,500 ⇒換算¥486,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

KEY FINDINGSThe global hyperphosphatemia drugs market is expected to grow at a CAGR of 16.06 % during the forecast period of 2018-2026. The market is expected to be worth $xx million by the year 2026. Increasing prevalence of chronic diseases, unmet medical needs, a high proportion of the elderly population and the rise in public awareness are the major drivers for the hyperphosphatemia drugs market.
MARKET INSIGHTS
The market segmentation is done on the basis of the formulation. The various types of phosphate binders include calcium-based phosphate binders, aluminium-based phosphate binders, magnesium-based phosphate binders, iron-based phosphate binders and other phosphate binders. Of these, the Calcium-based phosphate binder’s held the largest market share of xx% in 2017 and is expected to continue its dominance during the forecast period. The global hyperphosphatemia market is facing many restraints due to various limitations levied by the Food and Drug Administration (FDA) and the growing side effects of the hyperphosphatemia drugs observed in some patients. In spite of this, the Asia-Pacific hyperphosphatemia drug market is showing much promise in terms of making various opportunities available for the market to grow and expand.
REGIONAL INSIGHTS
The hyperphosphatemia drugs market in North America is expected to hold the largest share by the end of the forecast period due to changing dietary habits, increasing osteoporosis cases and a rising ageing population in this region. The Europe hyperphosphatemia drugs market is also fast growing at a CAGR of xx%. However, it is the Asia-Pacific market which is expected to propel the market growth, with the Indian hyperphosphatemia drugs market exhibiting the highest growth at a CAGR of xx% during the forecast period.
COMPETITIVE INSIGHTS
The major companies in the hyperphosphatemia drugs market include, Johnson And Johnson, Amag Pharmaceuticals, Cipla, Keryx Biopharmaceuticals, Sun Pharm Inc., Zeria Pharmaceutical, DSM Biotech Pharmacal , Ultragenyx, Fermenta Biotech Ltd, Pfizer Inc., Bruno Pharmaceutical Spa, Roche Diagnostics Corporation, Vifor Pharma, Sanofi R.H. Moore Drug Co., Shire, and Fresenius Medical Care.

【レポートの目次】

1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
2.5. ESTIMATION METHODOLOGY
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. NORTH AMERICA IS THE GLOBAL LEADER IN HYPERPHOSPHATEMIA DRUGS MARKET
3.2.2. CHINA IS THE LARGEST HEALTHCARE DRUGS AND EQUIPMENT MARKET IN THE ASIA-PACIFIC REGION
3.2.3. IRON-BASED HYPERPHOSPHATEMIA DRUGS IS A GAME CHANGER
4. MARKET DETERMINANTS
4.1. DRIVERS
4.1.1. GROWING PREVALENCE OF CHRONIC DISEASES
4.1.2. UNMET MEDICAL NEEDS
4.1.3. SKEWED POPULATION MIX TOWARDS ELDERLY PEOPLE
4.1.4. RISE IN PUBLIC AWARENESS
4.2. RESTRAINTS
4.2.1. LIMITATIONS LEVIED BY THE FOOD AND DRUG ADMINISTRATION(FDA)
4.2.2. GROWING SIDE EFFECTS OF THE HYPERPHOSPHATEMIA DRUGS
4.3. OPPORTUNITIES
4.3.1. ASIA PACIFIC REGIONS ARE EXPECTED TO PROPEL THE MARKET GROWTH
4.4. CHALLENGES
4.4.1. NON-ADHERENCE TO TREATMENT REGIMENS
4.4.2. SIDE EFFECTS OF DRUGS
4.4.3. LIMITED AVAILABILITY OF DRUGS
4.4.4. USE OF ADVANCED DIALYSIS TECHNIQUES
5. MARKET BY DOSAGE
5.1. SOLID
5.1.1. TABLET
5.1.2. POWDER
5.2. LIQUID
5.2.1. SOLUTION
6. MARKET SEGMENTATION
6.1. MARKET BY FORMULATION 2018-2026
6.1.1. CALCIUM-BASED PHOSPHATE BINDERS
6.1.2. ALUMINIUM-BASED PHOSPHATE BINDERS
6.1.3. MAGNESIUM-BASED PHOSPHATE BINDERS
6.1.4. IRON-BASED PHOSPHATE BINDERS
6.1.5. OTHER PHOSPHATE BINDERS
7. KEY ANALYTICS
7.1. PORTER’S FIVE FORCE MODEL
7.1.1. THREAT OF NEW ENTRANTS
7.1.2. BARGAINING POWER OF BUYERS
7.1.3. BARGAINING POWER OF SUPPLIERS
7.1.4. THREAT OF SUBSTITUTE PRODUCT
7.1.5. INTENSITY OF COMPETITIVE RIVALRY
7.2. OPPORTUNITY MATRIX
7.3. KEY BUYING CRITERIA
7.3.1. APPLICATION
7.3.2. PRICING
7.3.3. EFFECTIVENESS
7.3.4. AVAILABILITY
7.4. STRATEGIC RECOMMENDATION & STRATEGIC CONCLUSIONS
7.5. MARKET TRENDS
7.5.1. PATIENT ASSISTANCE PROGRAMS
7.5.2. STRATEGIC ALLIANCES
7.5.3. INCREASE IN R&D
8. GEOGRAPHIC ANALYSIS
8.1. NORTH AMERICA
8.1.1. UNITED STATES
8.1.2. CANADA
8.2. EUROPE
8.2.1. UNITED KINGDOM
8.2.2. FRANCE
8.2.3. GERMANY
8.2.4. SPAIN
8.2.5. ITALY
8.2.6. REST OF EUROPE (ROE)
8.3. ASIA PACIFIC
8.3.1. INDIA
8.3.2. CHINA
8.3.3. JAPAN
8.3.4. AUSTRALIA
8.3.5. REST OF APAC
8.4. REST OF THE WORLD
8.4.1. LATIN AMERICA
8.4.2. MIDDLE EAST AND NORTH AMERICA (MENA)
8.4.3. REST OF AFRICA
9. COMPANY PROFILES
9.1. COMPETITIVE LANDSCAPE
9.1.1. MARKET SHARE ANALYSIS
9.2. BRUNO FARMACEUTICI SPA
9.2.1. OVERVIEW
9.2.2. PRODUCT PORTFOLIO
9.2.3. SCOT ANALYSIS
9.2.4. STRATEGIC INITIATIVES
9.3. FERMENTA BIOTECH LTD
9.3.1. OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. SCOT ANALYSIS
9.3.4. STRATEGIC INITIATIVES
9.4. AMAG PHARMACEUTICALS
9.4.1. OVERVIEW
9.4.2. PRODUCT PORTFOLIO
9.4.3. SCOT ANALYSIS
9.4.4. STRATEGIC INITIATIVES
9.5. JOHNSON AND JOHNSON
9.5.1. COMPANY OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. SCOT ANALYSIS
9.5.4. STRATEGIC INITIATIVES
9.6. SANOFI
9.6.1. OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. SCOT ANALYSIS
9.6.4. STRATEGIC INITIATIVES
9.7. SHIRE
9.7.1. OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. SCOT ANALYSIS
9.7.4. STRATEGIC INITIATIVES
9.8. FRESENIUS MEDICAL CARE
9.8.1. OVERVIEW
9.8.2. PRODUCT PORTFOLIO
9.8.3. SCOT ANALYSIS
9.8.4. STRATEGIC INITIATIVES
9.9. CIPLA
9.9.1. OVERVIEW
9.9.2. PRODUCT PORTFOLIO
9.9.3. SCOT ANALYSIS
9.9.4. STRATEGIC INITIATIVES
9.10. PFIZER INC.
9.10.1. OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. SCOT ANALYSIS
9.10.4. STRATEGIC INITIATIVES
9.11. ROCHE DIAGNOSTICS CORPORATION
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. SCOT ANALYSIS
9.11.4. STRATEGIC INITIATIVES
9.12. BIOTECH PHARMACAL
9.12.1. OVERVIEW
9.12.2. PRODUCTS PORTFOLIO
9.12.3. SCOT ANALYSIS
9.12.4. STRATEGIC INITIATIVES
9.13. SUN PHARMACEUTICAL INDUSTRIES LTD
9.13.1. OVERVIEW
9.13.2. PRODUCTS PORTFOLIO
9.13.3. SCOT ANALYSIS
9.13.4. STRATEGIC INITIATIVES
9.14. ZERIA PHARMACEUTICAL
9.14.1. OVERVIEW
9.14.2. PRODUCT PORTFOLIO
9.14.3. SCOT ANALYSIS
9.14.4. STRATEGIC INITIATIVES
9.15. KERYX BIOPHARMACEUTICALS INC
9.15.1. OVERVIEW
9.15.2. PRODUCT PORTFOLIO
9.15.3. SCOT ANALYSIS
9.15.4. STRATEGIC INITIATIVES
9.16. ROYAL DSM N.V.
9.16.1. OVERVIEW
9.16.2. PRODUCT PORTFOLIO
9.16.3. SCOT ANALYSIS
9.16.4. STRATEGIC INITIATIVES
9.17. ULTRAGENYX PHARMACEUTICAL INC.
9.17.1. OVERVIEW
9.17.2. PRODUCT PORTFOLIO
9.17.3. SCOT ANALYSIS
9.17.4. STRATEGIC INITIATIVES

LIST OF TABLES
TABLE 1 GLOBAL HYPERPHOSPHATEMIA DRUG MARKET BY GEOGRAPHY 2018-2026($ MILLION)
TABLE 2 IRON-BASED HYPERPHOSPHATEMIA DRUG APPROVAL STATUS 2014-2017
TABLE 3 GLOBAL PREVALENCE OF DIABETES 2015 AND 2035 (MILLIONS)
TABLE 4 WORLDWIDE POPULATION AGED 80 AND ABOVE 1950-2050 (MILLIONS)
TABLE 5 PHOSPHOROUS LEVELS IN SELECT FOODS
TABLE 6 GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY FORMULATION 2018-2026($ MILLION)
TABLE 7 GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET IN CALCIUM-BASED PHOSPHATE BINDERS 2018-2026($ MILLION)
TABLE 8 GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET IN ALUMINUM-BASED PHOSPHATE BINDERS 2018-2026($ MILLION)
TABLE 9 GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET IN MAGNESIUM-BASED PHOSPHATE BINDERS 2018-2026($ MILLION)
TABLE 10 GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET IN IRON-BASED PHOSPHATE BINDERS 2018-2026($ MILLION)
TABLE 11 GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET IN OTHER PHOSPHATE BINDERS 2018-2026($ MILLION)
TABLE 12 PIPELINE PORTFOLIO OF HYPERPHOSPHATEMIA DRUGS
TABLE 13 GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET, BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 14 NORTH AMERICA HYPERPHOSPHATEMIA DRUGS MARKET 2018-2026($ MILLION)
TABLE 15 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET 2018-2026($ MILLION)
TABLE 16 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET 2018-2026($ MILLION)
TABLE 17 PER CAPITA CONSUMPTION OF DAIRY PRODUCTS IN AUSTRALIA
TABLE 18 REST OF THE WORLD HYPERPHOSPHATEMIA DRUGS MARKET 2018-2026($ MILLION)

LIST OF FIGURES
FIGURE 1 RATE OF ADHERENCE TO PHOSPHATE BINDERS
FIGURE 2 DIAGNOSIS AND CLINICAL INDICATORS OF CHRONIC KIDNEY DISEASE
FIGURE 3 GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET IN CALCIUM-BASED PHOSPHATE BINDERS 2018-2026($ MILLION)
FIGURE 4 GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET IN ALUMINUM-BASED PHOSPHATE BINDERS 2018-2026($ MILLION)
FIGURE 5 GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET IN MAGNESIUM-BASED PHOSPHATE BINDERS 2018-2026($ MILLION)
FIGURE 6 GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET IN IRON-BASED PHOSPHATE BINDERS 2018-2026($ MILLION)
FIGURE 7 GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET IN OTHER PHOSPHATE BINDERS 2018-2026($ MILLION)
FIGURE 8 PORTERS 5 FORCE MODEL OF HYPERPHOSPHATEMIA MARKET
FIGURE 9 INVESTMENT PREPOSITION ACROSS REGIONS 2018-2026
FIGURE 10 GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET SHARE, BY GEOGRAPHY 2017 & 2026 (%)
FIGURE 11 NORTH AMERICA HYPERPHOSPHATEMIA DRUGS MARKET 2018-2026($ MILLION)
FIGURE 12 UNITED STATES HYPERPHOSPHATEMIA DRUGS MARKET 2018-2026($ MILLION)
FIGURE 13 CANADA HYPERPHOSPHATEMIA DRUGS MARKET 2018-2026($ MILLION)
FIGURE 14 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET 2018-2026($ MILLION)
FIGURE 15 UNITED KINGDOM HYPERPHOSPHATEMIA DRUGS MARKET 2018-2026($ MILLION)
FIGURE 16 FRANCE HYPERPHOSPHATEMIA DRUGS MARKET 2018-2026($ MILLION)
FIGURE 17 GERMANY HYPERPHOSPHATEMIA DRUGS MARKET 2018-2026($ MILLION)
FIGURE 18 SPAIN HYPERPHOSPHATEMIA DRUGS MARKET 2018-2026($ MILLION)
FIGURE 19 ITALY HYPERPHOSPHATEMIA DRUGS MARKET 2018-2026($ MILLION)
FIGURE 20 REST OF EUROPE HYPERPHOSPHATEMIA DRUGS MARKET 2018-2026($ MILLION)
FIGURE 21 ASIA-PACIFIC HYPERPHOSPHATEMIA DRUGS MARKET 2018-2026($ MILLION)
FIGURE 22 AGE WISE DISTRIBUTION OF ELDERLY POPULATION IN INDIA
FIGURE 23 INDIA HYPERPHOSPHATEMIA DRUGS MARKET 2018-2026($ MILLION)
FIGURE 24 CHINA HYPERPHOSPHATEMIA DRUGS MARKET 2018-2026($ MILLION)
FIGURE 25 JAPAN HYPERPHOSPHATEMIA DRUGS MARKET 2018-2026($ MILLION)
FIGURE 26 NUMBER OF FRACTURES DUE TO OSTEOPOROSIS AND OSTEOPENIA ($ MILLION)
FIGURE 27 AUSTRALIA HYPERPHOSPHATEMIA DRUGS MARKET 2018-2026($ MILLION)
FIGURE 28 ROAPAC HYPERPHOSPHATEMIA DRUGS MARKET 2018-2026($ MILLION)
FIGURE 29 REST OF THE WORLD HYPERPHOSPHATEMIA DRUGS MARKET 2018-2026($ MILLION)
FIGURE 30 LATIN AMERICA HYPERPHOSPHATEMIA DRUGS MARKET 2018-2026($ MILLION)
FIGURE 31 MENA HYPERPHOSPHATEMIA DRUGS MARKET 2018-2026($ MILLION)
FIGURE 32 REST OF AFRICA HYPERPHOSPHATEMIA DRUGS MARKET 2018-2026($ MILLION)
FIGURE 33 MARKET SHARE ANALYSIS OF KEY PLAYERS 2017 (%)



【レポートのキーワード】

高リン血症治療薬

★調査レポート[世界の高リン血症治療薬市場] (コード:INKW807061)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の高リン血症治療薬市場]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆